Medicinal Chemistry News and Research RSS Feed - Medicinal Chemistry News and Research

Brain network measures placebo effects in Parkinson's disease patients

Brain network measures placebo effects in Parkinson's disease patients

Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. [More]
ACS Infectious Diseases journal highlights chemistry and collaborative research area

ACS Infectious Diseases journal highlights chemistry and collaborative research area

The American Chemical Society (ACS) announced today that Courtney Aldrich, Ph.D., will head the brand-new, web-only journal ACS Infectious Diseases as editor-in-chief. With the first issue slated for publication in January 2015, the pioneering journal will meet a growing demand for a place to publish top-notch chemistry-focused infectious diseases research. [More]
New chemical compound protects against blindness and diabetes in animals

New chemical compound protects against blindness and diabetes in animals

In a new study led by UC San Francisco scientists, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats and mice, against degenerative forms of blindness and diabetes. [More]
Exeter scientists find health benefits in rotten egg gas

Exeter scientists find health benefits in rotten egg gas

It may smell of flatulence and have a reputation for being highly toxic, but when used in the right tiny dosage, hydrogen sulfide is now being being found to offer potential health benefits in a range of issues, from diabetes to stroke, heart attacks and dementia. A new compound (AP39), designed and made at the University of Exeter, could hold the key to future therapies, by targeting delivery of very small amounts of the substance to the right (or key) places inside cells. [More]

Peakdale Molecular reports significant growth in demand for its medicinal chemistry services

Peakdale Molecular, a leading UK provider of medicinal chemistry and chemistry services, is celebrating its most successful year ever for revenues and earnings since the company’s inception in 1992. [More]
Syngene International, Bristol-Myers Squibb extend drug discovery and development collaboration

Syngene International, Bristol-Myers Squibb extend drug discovery and development collaboration

Bristol-Myers Squibb and Syngene International, India's largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India. [More]
P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to injury is necessary for preserving life, but blood platelets that are over-active, or activated inappropriately because of unstable plaque, can lead to heart attacks and strokes. [More]
New report raises important questions about transcranial direct current stimulation

New report raises important questions about transcranial direct current stimulation

Over the past several decades, neurostimulation techniques such as transcranial direct current stimulation (tDCS) have gradually gained favour in the public eye. In a new report, published yesterday in the prestigious scientific journal Neuron, IRCM ethics experts raise important questions about the rising tide of tDCS coverage in the media, while regulatory action is lacking and ethical issues need to be addressed. [More]
NIH award reflects urgency of overcoming infections that resist drug treatment

NIH award reflects urgency of overcoming infections that resist drug treatment

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health has selected infectious disease expert David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, to lead a major research effort aimed at developing new forms of antibiotics to regain the upper hand over deadly bacteria that have become resistant to current treatments. [More]
Georgia State researcher receives grant to develop novel therapeutics against RSV infection

Georgia State researcher receives grant to develop novel therapeutics against RSV infection

Dr. Richard Plemper, a professor in the new Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.83 million federal grant to develop novel therapeutics against Respiratory Syncytial Virus (RSV) infection. [More]
New insight provides potential to improve treatment for sepsis

New insight provides potential to improve treatment for sepsis

In a review published in the April issue of Immunity, Kevin J. Tracey, MD, president of The Feinstein Institute for Medical Research, says it's time to take a fresh look at the medical community's approach to treating sepsis, which kills millions worldwide every year, including more than 200,000 Americans. [More]
Scientists develop novel antiviral drug that may prevent spreading of measles

Scientists develop novel antiviral drug that may prevent spreading of measles

A novel antiviral drug may protect people infected with the measles from getting sick and prevent them from spreading the virus to others, an international team of researchers says. [More]
Study shows critical role of immune system in protecting against viruses and cancer cells

Study shows critical role of immune system in protecting against viruses and cancer cells

​A team of researchers at the IRCM, led by Andr- Veillette, MD, explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases. [More]
Research findings help explain rare genetic disorder that causes immunodeficiency syndrome

Research findings help explain rare genetic disorder that causes immunodeficiency syndrome

IRCM researchers led by Javier M. Di Noia, PhD, uncovered a new function of AID, a crucial enzyme for the immune response. The discovery, recently published by the scientific journal Proceedings of the National Academy of Sciences, helps explain a rare genetic disorder that causes an immunodeficiency syndrome. [More]
SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

Two grants from the National Institutes of Health will allow Saint Louis University researchers to build on breakthroughs in understanding the hepatitis B virus and begin the search for a drug to cure - not just halt - the illness. [More]
IDRI awarded grant extension of $3.4M for identifying new leads and drug targets for tuberculosis

IDRI awarded grant extension of $3.4M for identifying new leads and drug targets for tuberculosis

IDRI's​ drug discovery efforts continue to grow with a recently awarded grant extension of $3.4 million from the Bill & Melinda Gates Foundation. The additional funding was awarded to Tanya Parish, Ph.D., IDRI's Vice President of Drug Discovery, and supplements an earlier grant awarded in 2010, for a total of $7.8 million. [More]
CRO services division of Galapagos to be acquired by Charles River Laboratories

CRO services division of Galapagos to be acquired by Charles River Laboratories

Charles River Laboratories International, Inc. announced today that it has entered into a definitive agreement to acquire the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. [More]
UNIGE discovers new class of molecules toxic for Plasmodium pathogen

UNIGE discovers new class of molecules toxic for Plasmodium pathogen

​The malaria parasite is particularly pernicious since it is built to develop resistance to treatments. The lack of new therapeutic approaches also contributes to the persistence of this global scourge. [More]
Monash University research offers new hope to people with heart attacks

Monash University research offers new hope to people with heart attacks

Melbourne scientists are a step closer to creating a new drug to stop a heart attack in its tracks and reduce the damage caused, without any side effects. [More]

Debiopharm plans to expand, optimize activities at Martigny manufacturing facility

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments, has announced its decision to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial high-value added activities or companies in the pharmaceutical, biotech or medtech field. [More]